Trial
NCT04400799
Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Zurich
Collaborators
Insel Gruppe AG, University Hospital Bern; University Hospital, Geneva; Centre Hospitalier Universitaire Vaudois; University Hospital, Basel, Switzerland; Oncology Institute of Southern Switzerland; Clinica Luganese Moncucco; University Hospital Freiburg; Mainz University
Condition
COVID-19
Intervention
Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml
Why stopped
due to results from interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-25